Advice
following a full submission
colecalciferol (Fultium-D3®) is accepted for use within NHS Scotland.
Indication under review: In adults, the elderly and adolescents for the prevention and treatment of vitamin D deficiency and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency.
The therapeutic use and safety profile of colecalciferol as a treatment for vitamin D deficiency and as an adjunctive treatment in osteoporosis is well established. There are no comparative data for Fultium-D3® as it is the first licensed oral vitamin D monotherapy formulation.
Download detailed advice146KB (PDF)
Medicine details
- Medicine name:
- colecalciferol (Fultium-D3)
- SMC ID:
- 801/12
- Indication:
- In adults, the elderly and adolescents for the prevention and treatment of vitamin D deficiency and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency.
- Pharmaceutical company
- Internis Pharmaceuticals Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 September 2012